Valuation: Assembly Biosciences, Inc.

Market Cap 683M 585M 545M 500M 940M 65.32B 959M 6.47B 2.52B 32.74B 2.56B 2.51B 108B P/E 2026 *
-58.5x
P/E 2027 * -11.5x
Enterprise Value 683M 585M 545M 500M 940M 65.32B 959M 6.47B 2.52B 32.74B 2.56B 2.51B 108B EV / Sales 2026 *
11x
EV / Sales 2027 * 21.2x
Free-Float
72.34%
Yield 2026 *
-
Yield 2027 * -
1 day-0.92%
1 week+11.95%
Current month+33.53%
1 month+33.80%
3 months+27.68%
6 months+16.63%
Current year-1.41%
1 week 29.83
Extreme 29.83
34.57
1 month 24.5
Extreme 24.5
34.57
Current year 21.8
Extreme 21.795
34.68
1 year 20.23
Extreme 20.23
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
47.28
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
4/6/26 Free

Director

8,000 0.0514%
29/3/26 Free

Chief Technology Officer

26,000 0.1671%
8/8/25 BuyCompany 4,591,840 72.2409%
Change 5-day change 1-year change 3-year change Capi.($)
-0.92%+11.95%+28.22%+200.45% 683M
+1.14%+2.27%+2.38%+24.14% 51.22B
-1.36%+4.82%+485.55%+614.84% 45.38B
-2.04%+3.69%+19.34%+91.23% 41.97B
+2.72%+6.02%+33.33%+19.66% 42.15B
0.00%-3.91%+18.49%+47.98% 31.95B
-1.85%+3.48% - - 16.73B
+0.72%+5.27%+31.55%+145.37% 17.1B
+3.06%+3.88%+5.81%+35.00% 14.76B
+0.50%+3.62%+82.64%+46.53% 13.91B
Average +0.20%+4.11%+78.59%+136.13% 27.59B
Weighted average by Cap. +0.21%+3.20%+103.26%+150.95%

Financials

2026 *2027 *
Net sales 62.02M 53.1M 49.54M 45.46M 85.43M 5.93B 87.11M 588M 229M 2.97B 233M 228M 9.85B 32.25M 27.61M 25.76M 23.64M 44.42M 3.09B 45.3M 306M 119M 1.55B 121M 118M 5.12B
Net income -10.61M -9.09M -8.48M -7.78M -14.62M -1.02B -14.9M -101M -39.2M -509M -39.84M -38.98M -1.68B -60.26M -51.6M -48.14M -44.17M -83.01M -5.77B -84.64M -571M -223M -2.89B -226M -221M -9.57B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
20/08/26 USD 33.53 -0.92% 215,023
19/08/26 USD 33.84 +5.32% 384,565
18/08/26 USD 32.13 +7.06% 484,813
17/08/26 USD 30.01 -8.92% 304,523
14/08/26 USD 32.95 +10.02% 559,108
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
33.53USD
Average target price
50.00USD
Spread / Average Target
+49.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock